Skip to main content

Table 1 Demographics of Sample Cohort

From: Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature

Patient #

1

2

3

4

5

6

7

8

Age at diagnosis

2 months

16 years

8 years

5 years

14 years

8 years

5 years

13 years

Sex

Male

Male

Male

Female

Male

Male

Female

Female

Ethnicity

Caucasian

Caucasian

Caucasian

Caucasian

Caucasian

Caucasian

Hispanic

Caucasian

Palpable purpura

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Hematuria and/or proteinuria

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Renal biopsy pathology

Not done

WHO Class I

WHO Class III

WHO Class III

WHO Class III/IV

WHO Class II

WHO Class II

Not done

Arthritis

No

No

Yes

No

No

No

No

Yes

GI bleed/distress

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Long term CS use

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Immuno-modulators (Months of DMARD prior to 1st RTX)

MTX [2]; MMF [4]

MTX [1]

AZA [4]

CTX (1 dose)

None

MTX [2]; MMF [7]

MTX [2]; MMF (post); IVIG (post)

MTX (> 3 years intermittent)

  1. AZA azathioprine, CS corticosteroid, CTX cyclophosphamide, GI gastrointestinal, IVIG intravenous immunoglobulin, MMF mycophenolate mofetil, MTX methotrexate, DMARD disease modifying anti-rheumatic drug